Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.

Khodadoust MS, Rook AH, Porcu P, Foss F, Moskowitz AJ, Shustov A, Shanbhag S, Sokol L, Fling SP, Ramchurren N, Pierce R, Davis A, Shine R, Li S, Fong S, Kim J, Yang Y, Blumenschein WM, Yearley JH, Das B, Patidar R, Datta V, Cantu E, McCutcheon JN, Karlovich C, Williams PM, Subrahmanyam PB, Maecker HT, Horwitz SM, Sharon E, Kohrt HE, Cheever MA, Kim YH.

J Clin Oncol. 2019 Sep 18:JCO1901056. doi: 10.1200/JCO.19.01056. [Epub ahead of print]

PMID:
31532724
2.

ORAL 5-AZACYTIDINE AND ROMIDEPSIN EXHIBIT MARKED ACTIVITY IN PATIENTS WITH PTCL: A MULTICENTER PHASE I STUDY.

O'Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, Deng C, Montanari F, Amengual JE, Kim HA, Rada AM, Khan K, Jacob AT, Malanga M, Francescone M, Nandakumar R, Soderquist C, Park DC, Bhagat G, Cheng B, Risueno A, Menezes D, Shustov AR, Sokol L, Scotto L.

Blood. 2019 Aug 30. pii: blood.2019001285. doi: 10.1182/blood.2019001285. [Epub ahead of print]

PMID:
31471376
3.

T-cell prolymphocytic leukemia presenting with erythematous patches, plaques, and erythema gyratum-like lesions masquerading as Sézary syndrome.

Cohen L, Haque A, Ma S, Zhang L, Sokol L, Seminario-Vidal L.

JAAD Case Rep. 2019 Aug 5;5(8):686-690. doi: 10.1016/j.jdcr.2019.06.004. eCollection 2019 Aug. No abstract available.

4.

Skin-first nodulotumoral adult T-cell lymphoma mimicking cutaneous T-cell lymphoma.

Cohen L, Chen PL, Zhang L, Sokol L, Seminario-Vidal L.

JAAD Case Rep. 2019 Jul 31;5(8):650-652. doi: 10.1016/j.jdcr.2019.05.017. eCollection 2019 Aug. No abstract available.

5.

High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma.

Mirza AS, Dholaria BR, Hussaini M, Mushtaq S, Horna P, Ravindran A, Kumar A, Ayala E, Kharfan-Dabaja MA, Bello C, Chavez JC, Sokol L.

Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):e513-e520. doi: 10.1016/j.clml.2019.03.021. Epub 2019 Mar 29.

PMID:
31253594
6.

Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.

Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, Sokol L, Joyce R, Avigan D, Neuberg D, Takvorian RW, Hochberg EP, Bello CM.

Blood. 2019 Aug 15;134(7):606-613. doi: 10.1182/blood.2019001272. Epub 2019 Jun 11.

PMID:
31186274
7.

Evolving paradigm in thrombophilia screening.

Ashraf N, Visweshwar N, Jaglal M, Sokol L, Laber D.

Blood Coagul Fibrinolysis. 2019 Jul;30(5):249-252. doi: 10.1097/MBC.0000000000000809.

8.

Co-expression of cytokeratin and vimentin in colorectal cancer highlights a subset of tumor buds and an atypical cancer-associated stroma.

Meyer SN, Galván JA, Zahnd S, Sokol L, Dawson H, Lugli A, Zlobec I.

Hum Pathol. 2019 May;87:18-27. doi: 10.1016/j.humpath.2019.02.002. Epub 2019 Feb 20.

PMID:
30794893
9.

Blastic Plasmacytoid Dendritic Cell Neoplasm.

Kerr D 2nd, Zhang L, Sokol L.

Curr Treat Options Oncol. 2019 Feb 4;20(1):9. doi: 10.1007/s11864-019-0605-x. Review.

PMID:
30715612
10.

EndoDB: a database of endothelial cell transcriptomics data.

Khan S, Taverna F, Rohlenova K, Treps L, Geldhof V, de Rooij L, Sokol L, Pircher A, Conradi LC, Kalucka J, Schoonjans L, Eelen G, Dewerchin M, Karakach T, Li X, Goveia J, Carmeliet P.

Nucleic Acids Res. 2019 Jan 8;47(D1):D736-D744. doi: 10.1093/nar/gky997.

11.

Naïve/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: Putative cell of origin overlaps disease classification.

Horna P, Moscinski LC, Sokol L, Shao H.

Cytometry B Clin Cytom. 2019 May;96(3):234-241. doi: 10.1002/cyto.b.21738. Epub 2018 Oct 16.

PMID:
30328260
12.

Telemedicine in Neurological Disorders: Opportunities and Challenges.

Chirra M, Marsili L, Wattley L, Sokol LL, Keeling E, Maule S, Sobrero G, Artusi CA, Romagnolo A, Zibetti M, Lopiano L, Espay AJ, Obeidat AZ, Merola A.

Telemed J E Health. 2019 Jul;25(7):541-550. doi: 10.1089/tmj.2018.0101. Epub 2018 Aug 23.

PMID:
30136898
13.

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.

Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B.

Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):569-575.e1. doi: 10.1016/j.clml.2018.05.023. Epub 2018 Jun 6.

PMID:
30122201
14.

The advances in therapy of blastic plasmacytoid dendritic cell neoplasm.

Kerr D 2nd, Sokol L.

Expert Opin Investig Drugs. 2018 Sep;27(9):733-739. doi: 10.1080/13543784.2018.1512970. Epub 2018 Aug 27. Review.

PMID:
30118336
15.

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators.

Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Erratum in: Lancet Oncol. 2018 Nov;19(11):e581.

PMID:
30100375
16.

Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study.

Basiorka AA, McGraw KL, Abbas-Aghababazadeh F, McLemore AF, Vincelette ND, Ward GA, Eksioglu EA, Sallman DA, Ali NA, Padron E, Pinilla-Ibarz J, Komrokji R, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Sokol L, Wei S, Fridley B, List AF.

Lancet Haematol. 2018 Sep;5(9):e393-e402. doi: 10.1016/S2352-3026(18)30109-1. Epub 2018 Jul 30.

17.

Clonal T-cell Large Granular Lymphocytic Disorders Manifesting in Patients with HIV-1 Infection: Case Series and Review of the Literature.

Rose A, Isenalumhe L, Van den Bergh M, Sokol L.

Mediterr J Hematol Infect Dis. 2018 Jun 21;10(1):e2018036. doi: 10.4084/MJHID.2018.036. eCollection 2018.

18.

Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study.

Sandoval-Sus JD, Faramand R, Chavez J, Puri S, Parra P, Sokol L, Kharfan-Dabaja MA, Shah B, Ayala E.

Leuk Lymphoma. 2019 Feb;60(2):309-316. doi: 10.1080/10428194.2018.1468894. Epub 2018 Jul 2.

PMID:
29963932
19.

Disseminated Cutaneous Lesions in a Patient With a Medical History of Myelodysplastic Syndrome.

Yun S, Sokol L, Zhang L.

JAMA Oncol. 2018 Sep 1;4(9):1281-1282. doi: 10.1001/jamaoncol.2018.0488. No abstract available.

PMID:
29800978
20.

Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment.

Juárez-Salcedo LM, Sokol L, Chavez JC, Dalia S.

Cancer Control. 2018 Jan-Mar;25(1):1073274818778256. doi: 10.1177/1073274818778256.

21.

Sezary syndrome manifesting as posttransplant lymphoproliferative disorder.

Afiat TP, Zhang X, Zhang H, Ayala E, Zhang L, Sokol L.

Leuk Res Rep. 2018 May 1;9:72-75. doi: 10.1016/j.lrr.2018.04.006. eCollection 2018.

22.

Transformation of T-Cell Acute Lymphoblastic Lymphoma to Peripheral T-Cell Lymphoma: A Report of Two Cases.

Markow M, Mirza AS, Perez L, Shao H, Horna P, Anasetti C, Sokol L, Hussaini MO.

Case Rep Hematol. 2018 Feb 28;2018:9191582. doi: 10.1155/2018/9191582. eCollection 2018.

23.

Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma.

Kelling M, Sokol L, Dalia S.

Cancer Control. 2018 Jan-Mar;25(1):1073274818767879. doi: 10.1177/1073274818767879.

PMID:
29606020
24.

Deep brain stimulation in uncommon tremor disorders: indications, targets, and programming.

Artusi CA, Farooqi A, Romagnolo A, Marsili L, Balestrino R, Sokol LL, Wang LL, Zibetti M, Duker AP, Mandybur GT, Lopiano L, Merola A.

J Neurol. 2018 Nov;265(11):2473-2493. doi: 10.1007/s00415-018-8823-x. Epub 2018 Mar 6.

PMID:
29511865
25.

NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.

Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, Clemens MW, Dogan A, Greer JP, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, Mehta A, Mehta-Shah N, Oki Y, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2018 Feb;16(2):123-135. doi: 10.6004/jnccn.2018.0007.

PMID:
29439173
26.

Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.

Dholaria BR, Ayala E, Sokol L, Nishihori T, Chavez JC, Hussaini M, Kumar A, Kharfan-Dabaja MA.

Leuk Res. 2018 Apr;67:1-5. doi: 10.1016/j.leukres.2018.01.009. Epub 2018 Jan 31.

PMID:
29407180
27.

Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.

Panda A, Mehnert JM, Hirshfield KM, Riedlinger G, Damare S, Saunders T, Kane M, Sokol L, Stein MN, Poplin E, Rodriguez-Rodriguez L, Silk AW, Aisner J, Chan N, Malhotra J, Frankel M, Kaufman HL, Ali S, Ross JS, White EP, Bhanot G, Ganesan S.

J Natl Cancer Inst. 2018 Mar 1;110(3):316-320. doi: 10.1093/jnci/djx213.

28.

Chemotherapy-related anemia.

Visweshwar N, Jaglal M, Sokol L, Zuckerman K.

Ann Hematol. 2018 Feb;97(2):375-376. doi: 10.1007/s00277-017-3155-y. Epub 2017 Nov 4. No abstract available.

PMID:
29103107
29.

The hyaluronan-mediated motility receptor RHAMM promotes growth, invasiveness and dissemination of colorectal cancer.

Mele V, Sokol L, Kölzer VH, Pfaff D, Muraro MG, Keller I, Stefan Z, Centeno I, Terracciano LM, Dawson H, Zlobec I, Iezzi G, Lugli A.

Oncotarget. 2017 Aug 3;8(41):70617-70629. doi: 10.18632/oncotarget.19904. eCollection 2017 Sep 19.

30.

Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.

Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S.

Br J Haematol. 2017 Dec;179(5):781-789. doi: 10.1111/bjh.14954. Epub 2017 Oct 4.

PMID:
28980314
31.

Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies: A Review.

Bohra C, Sokol L, Dalia S.

Cancer Control. 2017 Oct-Dec;24(4):1073274817729901. doi: 10.1177/1073274817729901. Review.

32.

Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.

Foss F, Horwitz S, Pro B, Miles Prince H, Sokol L, Balser B, Wolfson J, Coiffier B.

J Hematol Oncol. 2017 Sep 18;10(1):154. doi: 10.1186/s13045-017-0518-8. No abstract available.

33.

The Parkinson Care Advocate: Integrating Care Delivery.

Sokol LL, Shapiro D, Young MJ, Wise AH, Hadelsberg UP, Kaufman Y, Espay AJ, Merola A.

Front Neurol. 2017 Jul 27;8:364. doi: 10.3389/fneur.2017.00364. eCollection 2017. No abstract available.

34.

Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1826-1838. doi: 10.1016/j.bbmt.2017.07.027. Epub 2017 Aug 7.

35.

Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials.

Van Heertum RL, Scarimbolo R, Wolodzko JG, Klencke B, Messmann R, Tunc F, Sokol L, Agarwal R, Strafaci JA, O'Neal M.

Drug Des Devel Ther. 2017 Jun 13;11:1719-1728. doi: 10.2147/DDDT.S136988. eCollection 2017.

36.

BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.

Kulkarni A, Al-Hraishawi H, Simhadri S, Hirshfield KM, Chen S, Pine S, Jeyamohan C, Sokol L, Ali S, Teo ML, White E, Rodriguez-Rodriguez L, Mehnert JM, Ganesan S.

Clin Cancer Res. 2017 Sep 15;23(18):5631-5638. doi: 10.1158/1078-0432.CCR-16-0758. Epub 2017 May 24.

37.

Digital analysis and epigenetic regulation of the signature of rejection in colorectal cancer.

Koelzer VH, Sokol L, Zahnd S, Christe L, Dawson H, Berger MD, Inderbitzin D, Zlobec I, Lugli A.

Oncoimmunology. 2017 Feb 6;6(4):e1288330. doi: 10.1080/2162402X.2017.1288330. eCollection 2017.

38.

CD4-Positive T-Cell Large Granular Lymphocytosis Mimicking Sezary Syndrome in a Patient With Mycosis Fungoides.

Zhang L, Van den Bergh M, Sokol L.

Cancer Control. 2017 Apr;24(2):207-212.

PMID:
28441377
39.

The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now.

Juárez-Salcedo LM, Sandoval-Sus J, Sokol L, Chavez JC, Dalia S.

Crit Rev Oncol Hematol. 2017 May;113:52-62. doi: 10.1016/j.critrevonc.2017.02.027. Epub 2017 Mar 9. Review.

PMID:
28427522
40.

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.

Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2017 Mar;15(3):293-311.

PMID:
28275031
41.

Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.

Shustov A, Coiffier B, Horwitz S, Sokol L, Pro B, Wolfson J, Balser B, Eisch R, Popplewell L, Prince HM, Allen SL, Piekarz R, Bates S.

Leuk Lymphoma. 2017 Oct;58(10):2335-2341. doi: 10.1080/10428194.2017.1295143. Epub 2017 Mar 7.

PMID:
28264616
42.

Optimizing antiviral agents for hepatitis B management in malignant lymphomas.

Ozoya OO, Chavez J, Sokol L, Dalia S.

Ann Transl Med. 2017 Feb;5(3):39. doi: 10.21037/atm.2016.12.25. Review.

43.

DNA profiling of tumor buds in colorectal cancer indicates that they have the same mutation profile as the tumor from which they derive.

Centeno I, Paasinen Sohns A, Flury M, Galván JA, Zahnd S, Koelzer VH, Sokol L, Dawson HE, Lugli A, Cathomas G, Zlobec I.

Virchows Arch. 2017 Mar;470(3):341-346. doi: 10.1007/s00428-017-2071-9. Epub 2017 Jan 27. No abstract available.

PMID:
28130698
44.

Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.

Foss F, Pro B, Miles Prince H, Sokol L, Caballero D, Horwitz S, Coiffier B.

Cancer Med. 2017 Jan;6(1):36-44. doi: 10.1002/cam4.939. Epub 2016 Dec 16.

45.

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.

Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF.

Blood. 2016 Dec 22;128(25):2960-2975. doi: 10.1182/blood-2016-07-730556. Epub 2016 Oct 13.

46.

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P.

J Natl Compr Canc Netw. 2016 Sep;14(9):1067-79.

PMID:
27587620
47.

Adult T-Cell Leukemia/Lymphoma: Rarely Encountered in the United States.

Roe C, Komrokji R, Zhang L, Price S, Sokol L.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S191-4. doi: 10.1016/j.clml.2016.02.010.

PMID:
27521318
48.

Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature.

Chavez JC, Sandoval-Sus J, Horna P, Dalia S, Bello C, Chevernick P, Sotomayor EM, Sokol L, Shah B.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S170-4. doi: 10.1016/j.clml.2016.02.024.

PMID:
27521314
49.

CT findings associated with blastic plasmacytoid dendritic cell neoplasm: a case report.

Jeong D, Choi JW, Jeong K, Sokol L.

Acta Radiol Open. 2016 Jul 26;5(7):2058460116657688. doi: 10.1177/2058460116657688. eCollection 2016 Jul.

50.

Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.

Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Iyer SP, Shustov AR, Wolfson J, Balser BE, Coiffier B.

Hematol Oncol. 2017 Dec;35(4):914-917. doi: 10.1002/hon.2320. Epub 2016 Jul 12. No abstract available.

Supplemental Content

Support Center